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Abstract
Background: Angiotensin-converting enzyme (ACE) metabolizes many peptides and plays a key role in blood pressure
regulation and vascular remodeling. Elevated ACE levels may be associated with an increased risk for different
cardiovascular or respiratory diseases, including asthma. Previously, a molecular mechanism underlying a 5-fold familial
increase of blood ACE was discovered: Pro1199Leu substitution enhanced the cleavage-secretion process. Carriers of this
mutation were Caucasians from Europe (mostly Dutch) or had European roots.
Methodology/Principal Findings: We have found a family of African-American descent whose affected members’ blood
ACE level was increased 13-fold over normal. In affected family members, codon TGG coding for Trp1197 was substituted in
one allele by TGA (stop codon). As a result, half of ACE expressed in these individuals had a length of 1196 amino acids and
lacked a transmembrane anchor. This ACE mutant is not trafficked to the cell membrane and is directly secreted out of cells;
this mechanism apparently accounts for the high serum ACE level seen in affected individuals. A haplotype of the mutant
ACE allele was determined based on 12 polymorphisms, which may help to identify other carriers of this mutation. Some
but not all carriers of this mutation demonstrated airflow obstruction, and some but not all have hypertension.
Conclusions/Significance: We have identified a novel Trp1197Stop mutation that results in dramatic elevation of serum
ACE. Since blood ACE elevation is often taken as a marker of disease activity (sarcoidosis and Gaucher diseases), it is
important for clinicians and medical scientists to be aware of alternative genetic causes of elevated blood ACE that are not
apparently linked to disease.
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Introduction
Angiotensin I-converting enzyme (ACE, CD143) is a Zn
2+
carboxydipeptidase which plays key roles in the regulation of
blood pressure and in the development of vascular pathology and
remodeling [1–3]. ACE is constitutively expressed on the surface
of endothelial cells, different absorptive epithelial and neuroepi-
thelial cells [4–7], and cells of the immune system (macrophages,
dendritic cells) [8–9]. Somatic ACE contains two catalytic centers
in N- and C-terminal domains [10]), whereas a short testis-specific
isoform expressed in germ cells contains an identical C-domain
and only one catalytic center [11–12]. ACE was assigned as a
common differentiation marker - CD143 [7,13].
Besides membrane-bound forms of ACE, blood and other
biological fluids contain a variable amount of soluble ACE. Serum
ACE originates likely from endothelial cells [14] by proteolytic
cleavage [15–16]. Soluble ACE from CHO cells transfected with
human somatic ACE cDNA and porcine somatic ACE have C-
termini consistent with cleavage of the Arg1203-Ser1204 peptide
bond in a stalk region near the transmembrane domain [17]. The
cleavage/secretion process is catalyzed by an unidentified
membrane-bound secretase [18]. Seminal fluid ACE, whose
concentration is 50-fold more than that of ACE in blood, likely
originates from epithelial cells of the epididymis, which express an
abundant amount of somatic ACE [19]. In healthy individuals, the
level of ACE in the blood is very stable [20], whereas
granulomatous diseases (sarcoidosis in particular) and Gaucher’s
disease lead to a significant increase of ACE activity in the blood
[21–24]. Serial serum ACE measurements now are an essential
tool for the diagnosis and monitoring the clinical course of
sarcoidosis [25–27].
Recently, a mutation in the stalk region of ACE – Pro1199Leu
[28–29] – explained a dramatic (5-fold) increase in ACE activity in
the blood of affected individuals from Holland [28], Germany
[30], and USA [31]. Despite the fact that people with this
mutation exhibit no clinical abnormalities [28], testing for this
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failure to appreciate that elevation of ACE level is genetically
determined in an affected individual may lead to false diagnosis of
neurosarcoidosis and consequently to unnecessary long-term
immunosuppressive treatment [30] or diagnostic procedures [32].
Here we report the identification of a new mutation in ACE,
namely, introduction of a stop codon after N1196, which leads to
immediate secretion of the ACE molecule rather than retention on
the cell membrane, resulting in a dramatic increase in ACE level
in the blood. Interestingly, highly elevated level of ACE in affected
individuals (more than 13-fold that in the normal population)




The study was approved by the Institutional Review Boards of
the University of Illinois at Chicago and the University of Chicago.
Ten volunteers without sarcoidosis were chosen as control subjects
for a study of sarcoidosis unrelated to this report. One volunteer
(subject N1) was found to have serum ACE activity higher than
400 mU/ml (normal range with Hip-His-Leu as a substrate was
8–60 mU/ml - ref. [33]). First- and second-degree relatives of
subject N1 were asked to participate in the present study to
analyze whether N1’s ACE mutation was associated with any
clinical phenotype. After giving written informed consent (or for
children, assent with parental/guardian permission), they were
interviewed and spirometry was performed. Blood was taken from
adults for determination of ACE activity in serum or plasma and
for genotyping. Saliva was obtained from children for genotyping.
ACE Activity Assay
ACE activity in human serum or plasma was measured using a
fluorimetric assay with two ACE substrates (5 mM Hip-His-Leu or
2 mM Z-Phe-His-Leu) [34–35]. Briefly, 20–40 ml aliquots of
serum or plasma, diluted 1/5–1/80 in PBS-BSA (0.1 mg/ml),
were added to 200 ml of ACE substrate and incubated for the
appropriate time at 37uC. The His-Leu product was quantified
fluorometrically.
Immunological Characterization of the Mutant ACE (Plate
Immunoprecipitation Assay)
96-well plates (Corning, Corning, NY) were coated with anti-
ACE mAbs via goat anti-mouse IgG (Pierce, Rockford, IL) bridge
[33] and incubated with serum/plasma samples or soluble ACE
secreted from CHO cells transfected with wild type or mutant
ACEs, which were equilibrated for ACE activity with Hip-His-Leu
as a substrate. After washing of unbound ACE, plate-bound ACE
activity was measured by adding a substrate for ACE (Hip-His-
Leu) directly into wells [33,36].
Sequencing and Genotyping
Genomic DNA was obtained either from whole blood (adults) or
saliva (children). The whole ACE gene (,24 Kb) was sequenced
in two individuals; genomic DNA was isolated from index subject
N1 and from patient DR, who has the Pro1199Leu mutation
(DNA kindly provided by Dr. R. Stein, Penobscot Bay Medical
Center, Rockport, ME) used as a positive control.
After the discovery of the mutation Trp1197Stop, genotyping of
subjects N1 and DR was performed by another PCR-based
restriction fragment length polymorphism assessment. The 292 bp
DNA fragment was amplified by PCR with primers Ex25_292Fw
(TCCGCACGGAGAACGA, exon 25) and Ex25_292Rv (CC-
TGCTGCGCATCCA, exon 26) using genomic DNA from
subjects N1, N3 (mother of N1), N2 (father of N1) and DR (an
unrelated individual with Pro1199Leu mutation). The restriction
endonuclease BsaHI (AcyI) cuts this 292 bp PCR product from
individual with native, wild-type ACE (N3) into two fragments of
235 bp and 57 bp. Subject DR with Pro1199Leu substitution has
mutated the last nucleotide in the recognition sequence of BsaHI
(AcyI): GACGCT* vs. GRCGYC. Subject N1 (Trp1197Stop) has
mutation of the first nucleotide in the recognition sequence of this
endonuclease: *AACGCC vs. GRCGYC. As a result, these two
mutations (G-to-A mutation in the position 3699 (leading to
Trp1197Stop substitution and C-to-T mutation at position 3705 -
leading to Pro1199Leu substitution) both eliminate the BsaHI (Acy
I) restriction site. Thus, restriction analysis with BsaHI can
distinguish an individual with these two mutations from individ-
uals with normal ACE, but cannot distinguish between these two
mutations - Pro1199Leu (DR) and Trp1197Stop (N1 and N2).
However, the restriction endonuclease BsrI cuts the 292 bp
PCR product from individuals with wild-type ACE (e.g., N3) in
the same place as endonuclease BsaHI (AcyI) also creating two
fragments of 235 bp and 57 bp. In contrast, mutation
Trp1197Stop disturbs the recognition sequence of BsrI: ACT-
GA*A vs. ACTGGN. At the same time, mutation P1199L has no
effect on BsrI digestion. Thus, restriction analysis with BsrI can
distinguish individuals with mutation Trp1197Stop (N1, N2) from
individuals with mutation Pro1199Leu (e.g., DR), but cannot
distinguish between mutation Pro1199Leu and native ACE (N3).
Both restrictases BsaHI (AcyI) and BsrI must be used to
differentiate mutations Trp1197Stop and Pro1199Leu and native
ACE.
Heterozygous reading was obtained from genomic DNA
sequence of the patient N1 (,24 Kb) in the SNPs rs4331 (exon
15), rs4353 (exon 20), rs4359 (intron 23), rs4362 (exon 24) and
rs4363 (intron 25).
Cladistic Analysis
To study similarities between the ACE haplotype of subject N1
and haplotype clusters (clades) that had been already found in
human population, we used a computational method for
minimizing the weighted sum of squares of the differences
between observed and expected pairwise distances between
samples and construction of the most parsimonious classification
trees using routines DNAPARS and DRAWGRAM, programs
included in the software package PHYLIP v3.67 [37]. Genomic
DNA from N1 patient was sequenced, and homozygous positions
in N1 were aligned with haplotypes of published clades.
Site-Directed Mutagenesis and In Vitro Analysis of the
Mutant ACEs
cDNAs encoding two mutant ACE proteins were created by: 1)
mutation of the Trp (TGG) codon at position 1197 to a stop codon
(TGA); 2) mutation of the Pro (CCG) codon at position 1199 to a
Leu (CTG) codon, in pACE-wt, an expression vector (based on
pcDNA3.1+/Hygro (Invitrogen Corp., Carlsbad, CA) containing
the full-length somatic ACE cDNA controlled by CMV early
promoter [39]. An oligonucleotide-directed mutagenesis system
(Quick Change site-directed mutagenesis kit, Stratagene, La Jolla,
CA) was used according to the manufacturer’s recommendation.




tisense) for the Trp1197Stop mutation; 59-GTACAACTGGA-
CGCTGAACTCCGCTCGCT-39 (sense) and 59-AGCGAGCG-
New ACE Mutation (Trp1197Stop)
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Leu mutation.
Plasmid DNA was sequenced and clones with desired mutation
were selected for each mutation.
Plasmids carrying the coding sequence for wild-type ACE and
above mutants were expressed in CHO cells using Plus Reagent
(Invitrogen Corp., Carlsbad, CA) for transient transfection and
generation of stable cell lines. CHO cell lines expressing WT ACE
and WTD (Gln1230X) have been previously described ([38] and
[16], respectively). Culture medium (Ultra-CHO medium, Cam-
brex Bio-Science, Walkersville, MD) from these cells was used as a
source of the secreted (soluble) ACE (wild type and mutants) for
biochemical and immunological characterization.
ACE Purification from Heparinized Plasma
ACE was isolated from heparinized plasma of individuals with
normal level of ACE, from subject N1, and from patients having
the Pro1199Leu mutation [28] using affinity chromatography on a
Lisinopril-Sepharose column. Briefly, plasma (5–45 ml) diluted in
HEPES (20 mM pH 7.5, NaCl 150 mM) was incubated with 5 ml
of Lisinopril-Sepharose and after intensive washing of unbound
proteins, ACE was eluted with 50 mM borate buffer, pH 9.5.
Western Blot Analysis of Mutant ACEs
All samples for SDS electrophoresis were equilibrated to a final
ACE activity of 200 mU/ml (Hip-His-Leu as a substrate) and were
run using gradient (4–15%) Tris-HCl pre-cast SDS PAGE gels
(Bio-Red Laboratories, Hercules, CA). After electrophoretic
transfer of proteins to microporous PVDF-Plus membranes, each
membrane was incubated in 10 mM Tris-HCl (pH 8.0) buffer
containing 150 mM NaCl, 0.05% Tween 20, and 5% dry milk
prior to incubation with hybridoma culture fluids overnight at
4uC. Subsequent steps were carried out with the biotin/
streptavidin system (Amresco, Solon, Ohio) and peroxidase
activity was developed using WestPico Super Signal Chemilumi-
nescense substrate (Pierce, Rockford, IL).
Results
Discovery of a Novel ACE Mutation that Leads to High
Serum ACE Activity
During determination of ACE activity in 10 volunteers without
sarcoidosis (participating ascontrolsubjects ina study of bloodACE
activity in sarcoidosis), we found one individual (female, African-
American, designated ‘‘subject N1’’) with extremely high ACE
activity – .13-fold greater than the mean ACE activity in the other
volunteers(Fig.1A).Recently,wereporteda newassaythatemploys
monoclonal antibodiy 1B3, recognizing an epitope on the stalk
region of ACE where the Pro1199Leu (P1199L) mutation occurs,
that identifieswithhigh selectivityand specificitythemutationinthe
stalk region, and thus distinguishes hereditary elevation of ACE
from that due to diseases [39]. We used this assay to analyze subject
N1’s blood ACE. Based on the immunoprecipitation of ACE by
mAb 1B3 (Fig. 1B–D), ACE from subject N1 seems to have a
mutation in the stalk region of ACE that is similar, but not identical,
to that of individuals having Pro1199Leu mutation. Note that the
1B3/B9 ratio for ACE from subject N1 was about half that of
patients having the P1199L mutation (Fig. 1D).
Immunological Characterization of the Novel ACE from
Subject N1
The result above indicates that the mutant ACE from subject
N1 is not immunologically identical to a previously known mutant
ACE nor to wt ACE. We therefore further characterized the
conformation of subject N1’s mutant ACE, using a panel of mAbs
directed against 16 different epitopes located on the N-and C-
domain of catalytically active human ACE - ‘‘conformational
fingerprint of ACE’’ (Danilov et al., manuscript in preparation).
As apparent in Fig. 2, the immunoprecipitation profiles of ACE
from subject N1 and of mutant P1199L ACE are similar but not
identical, and both differ dramatically from that of ACE from
other healthy volunteers. Note also that mutant Pro1199Leu ACE
is differentially immunoprecipitated by several mAbs vs wt ACE
(Fig. 2), and not only by mAb 1B3 as initially demonstrated [39]. It
is also important to observe that the conformational fingerprinting
of plasma ACE is quite different when plasma is collected from
heparinized vs. EDTA-anticoagulated blood, which might be
explained by the fact that depletion of Zn
2+ from the active centers
of N and C domains of ACE significantly changes a local
conformation of ACE molecule [40].
Sequencing of the ACE Gene of Subject N1
The novel conformational fingerprint of ACE from subject N1
(Figs. 1–2) suggested that N1 carries a novel ACE mutation located
close to Pro1199, within the epitope for mAb 1B3. We therefore
sequenced the ACE gene from subject N1 using genomic DNA,
and as a control for sequencing we also sequenced ACE gene from
a patient known to have the P1199L substitution. Sequence
analysis of the genomic DNA from subject N1 disclosed a G to A
mutation at position 3699 (nucleotide and amino acid numbering
according to [10]), which leads to the replacement of a codon
TGG for Tryptophan residue by a stop codon (TGA) at position
1197 in the stalk region of the mature ACE protein (Fig. 3B);
subject N1 was heterozygous for this mutation. Moreover,
sequence analysis of the complete coding region of the ACE gene
in this individual revealed that beside other known polymorphisms
that do not affect ACE levels, the G-A mutation at position 3699 is
the only mutation present in the coding region of the ACE gene.
As a result, half of ACE expressed in this patient had a length of
1196 amino acids and lacked the transmembrane anchor. Previous
studies show that an ACE mutant (wtD), that lacks the
transmembrane anchor-is not trafficked to the cell membrane
and is directly secreted into the circulation [16]. We presume that
a similar mechanism accounts for this subject N1’s high serum
ACE level. The Trp1197Stop (W1197X) mutation was not present
in family members with normal ACE levels (Fig. 4). The hyper-
ACE segregation pattern was compatible with autosomal domi-
nant inheritance (Fig. 4).
The mAb 1B3-based method (Figs. 1–2) allows us to identify
carriers of the novel W1197X mutation as well as P1199L
substitution, but do not allow us to distinguish between these two
mutations easily. To facilitate detection of the novel mutation, we
used restriction analysis of a PCR-amplified fragment of genomic
DNA spanning 292 bp including part of exon 25, intron 25, and
part of exon 26. Fig. 3C demonstrates that the restriction
endonucleases BsaHI (AcyI) and BsrI each cut the 292 bp PCR
product from an individual with wild-type ACE (Control-mother
of N1, Lane1) into two fragments of 235 bp and 57 bp. Both the
G3678A mutation (leading to W1197X; subjects N1-Lane 2, and
father of N1 –lane 3) and the C3683T mutation (leading to
P1199L-Lane 4) eliminate the BsaHI (AcyI) restriction site.
Therefore, restriction analysis with BsaHI (AcyI) can distinguish
individuals with either of these two mutations from individuals
with wt ACE, but cannot distinguish between these two mutations
(Fig. 3). For this purpose, we used another restriction endonucle-
ase, BsrI. The fifth nucleotide in the recognition sequence of BsrI is
mutated in DNA harboring the W1197Xp mutation – ACTGA*A
New ACE Mutation (Trp1197Stop)
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8282Figure 1. ACE activity and conformation in the heparinized human plasma. A. ACE activity in 10 samples of heparinized human plasma
from healthy volunteers was quantified using a spectrofluorometric assay with Hip-His-Leu (5 mM) and Z-Phe-His-Leu (2 mM) as substrates. Samples
were diluted 1/5 (N2-N10) and 1/80 ( N1). Data expressed as mU/ml (with ZPHL as a substrate) of whole plasma. The results are shown as means + SD
of several (3–4) experiments. * - p,0.05 in comparison with mean value for samples N2-N10. B–D. Precipitation of ACE activity from plasma samples
by mAbs 1B3 and 9B9. Heparinized plasma samples from of 10 volunteers were equilibrated according to 5 mU/ml of the ACE activity with Hip-His-
Leu as a substrate and incubated with a wells on the microtiter plate covered by mAbs 1B3 or 9B9 via goat-anti-mouse IgG; then precipitated ACE
activity was quantified by fluorimetric assay - plate precipitation assay [36,39]. Data are expressed as a percentage of ACE activity precipitation by
mAb 1B3 (B), mAb 9B9 (C) and as their ratio (D). Data are mean 6 SD of triplicates. As a positive control sample of pooled plasma sample from
several carriers of Pro1199Leu mutation of ACE [28], was used. * - p,0.05 in comparison with mean value for samples N2-N10.
doi:10.1371/journal.pone.0008282.g001
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the mutation leading to P1199L has no effect on restriction by
BsrI, as the mutation is located outside its recognition sequence.
Restriction analysis with these two endonucleases therefore allows
us to identify and to distinguish these two mutations unequivocally
(Fig. 3C).
Site-Directed Mutagenesis of Human Recombinant
Somatic ACE
To confirm the mechanism by which the novel W1197X
mutation might be responsible for the high plasma ACE level, we
prepared several mutants of somatic ACE that harbor mutations
near the stalk region. Table 1 demonstrates release/secretion
characteristics of the generated mutants from CHO cells
transfected with corresponding plasmids. The rate of ACE release
was dramatically increased in each mutant ACE: whereas ACE
activity released into the culture medium during 24 hrs cultivation
was only 11% per day for wild-type ACE, ACE release increased
to 49% per day for P1199L mutant and was more than 80% per
day for the W1197X, S1211X and Q1230X mutants (Table 1).
These data showed that all three ACE mutants lacking
transmembrane domains are released into the culture medium
practically completely, with minimal retention on the cell surface.
Immunological ‘‘conformational fingerprinting’’ of recombinant
mutant ACEs using 16 mAbs to different epitopes located on the
N- and C-domains (Fig. 5) confirms that changes in conformation
of ACE from subject N1 were due to the W1197X mutation.
Thus, mAb 1B3 recognizes an epitope on the C terminal part of
the C-domain of somatic ACE and is very sensitive to the
conformation of the C terminal end (39). We imagine that the
much shortened C terminal end of the Pro1199Leu or Trp1197X
mutants might unmask the epitope for 1B3, whereas the longer C
terminal end as in the case of Gln1230X might shield the binding
site. Besides changes in the immunoprecipitation of mutant
Trp1197Stop ACE by mAbs 1B3, 1B8 and 3F10, which are
directed to the region affected by this mutation, there are several
others mAbs whose binding is also changed – i1A8, i2H5, 5F1 (see
Fig. 5). Interestingly, these mAbs changed their binding also to
Figure 2. Conformational fingerprinting of mutant ACEs with a set of mAbs to ACE. Sixteen monoclonal antibodies were used to
precipitate ACE from plasma anticoagulated using EDTA or heparin as indicated. Immunoprecipitated ACE activity is presented as a normalized value
(‘‘binding ratio’’), to highlight differences in immunoprecipitation pattern (‘‘conformational fingerprint’’) among ACE variants from healthy volunteers
(‘‘Normal’’), from subject N1 (‘‘N1’’), or carriers of the Pro1199Leu mutation (‘‘Pro1199Leu’’). (A) ACE binding ratios observed for N1 normalized to
normal individuals; (B) ACE binding ratios observed for subjects with known Pro1199Leu mutation normalized to normal individuals; (C) ratio of ACE
precipitation from subject N1 to that from carriers of Pro1199Leu mutation. Data presented as a mean of 6–8 independent determinations. * p,0.05
indicates ratio shown is significantly different from 1. These ratio for any pair of samples with normal ACE or with any pair of samples with one
(Trp1197Stop) or another (Pro1199Leu) identical mutation was around 1.0 with no more than 10% of standard deviation (not shown).
doi:10.1371/journal.pone.0008282.g002
New ACE Mutation (Trp1197Stop)
PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8282Figure 4. Family tree of subject N1 with new (Trp1197Stop) mutation in ACE gene. Individuals with Trp1197Stop mutation are indicated by
red color. Genotyped individuals without Trp1197Stop mutation marked by blue color. Individuals found to have high level of serum ACE are marked
by upward pointing arrows. Individuals found to have normal level of serum ACE are marked by horizontal arrows. Following abbreviations are used
for known clinical diagnoses: HTN – hypertension, DM – diabetes mellitus, HD – heart disease, AFO – airflow obstruction, Asthma – asthma. ACE level
in the blood of children (C3–C5) was not tested due to ethical considerations. Among individuals in whom both genotyping and serum ACE
determination was performed, there was 100% concordance between presence or absence of the Trp1197Stop mutation and elevated or non-
elevated serum ACE levels, respectively.
doi:10.1371/journal.pone.0008282.g004
Figure 3. Organization of the identified mutations in ACE gene. Diagram shows intron-exon structure of human ACE1 gene and localization
of the ACE1 mutations. A. Y266x Het mutation in 5
th exon and nt1319–1322del TGGA Hom mutation in 8
th exon were described in [54] and
Pro1199Leu Het mutation in 25
th exon – in [28–29]. B. Heterozygous mutation Trp1197Stop (W1197x) in 25
th exon was revealed by the sequencing of
the whole ACE gene (,24 kb) and confirmed by the restriction analysis of the 292 bp PCR product flanking the part of exon 25 and intron 25 with
restriction endonucleases BsrI and BsaHI (AcyI) (C), which was performed with genomic DNA of healthy individual with normal ACE (mother of N1) (1),
patient N1 (2) and father of N1 (3) caring mutation Trp1197Stop, and carrier of Pro1199Leu mutation (4). Trp1197Stop (but not Pro1199Leu) mutation
abolished restriction site for BsrI.
doi:10.1371/journal.pone.0008282.g003
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think that some of the changes in pattern of ACE immunopre-
cipitation by 16 mAbs seen in mutants lacking transmembrane
anchor are likely due to the changes in glycosylation pattern of
mutated ACE. The time of traffic of mutated ACEs through
endoplasmic reticulum is much shorter than a wild-type ACE [41–
42,29] and as a result the glycosylation pattern of mutated ACEs is
different from wild-type ACE; this could result in differential
binding of some mAbs (i1A8, i2H5, and 5F1), because
glycosylation sites on Asn residues are included in their epitopes
[40,43–45].
Western Blot Analysis of Mutated ACEs
We performed Western blotting of ACE purified from plasma of
s u b j e c tN 1u s i n gt w om A b st od e n a t u r e dh u m a nA C E :m A b1 D 8 ,
which recognizes a sequential epitope at the beginning of C domain
[46], and mAb 5C8, which is directed to the C-terminal end of
soluble ACE and of which binding was dramatically decreased to
mutant P1199L ACE [47]. Binding of 5C8 was significantly
abolished with both P1199L and W1197X mutants, whereas mAb
1D8recognizedsimilarlybothwild-typeandmutantACE(Fig.6A,B).
Therefore, quantification of 5C8/1D8 binding ratio allowed us to
identify the carriers of either mutation (but not to distinguish between
them) using Western blotting of their blood ACE. The sensitivity of
ACE detection with these mAbs allowed us to use even unprocessed
blood from carriers of these mutations (not shown).
Analysis of Ethnic Origin for the Mutated ACE Haplotype
To find human populations which might include other carriers
of the W1197X mutation, we performed a haplotype-based
analysis of the paternal (mutant) allele of subject N1’s ACE gene.
To reconstruct this haplotype, we sequenced her ACE genomic
DNA and partially sequenced and genotyped both parents of N1.
A panel of 12 SNPs specific for the mutated paternal ACE allele of
N1 patient is shown in Table 2. To search for haplotype matches
of N1, we used publicly available data on four populations of
different ethnicity: Yorubans in Ibadan, Nigeria (YRI, n=90);
Japanese in Tokyo, Japan (JPT, n=45); Han Chinese in Beijing,
China (CHB, n=45); and Utah residents with ancestry from
northern and western Europe (Centre d’Etude du Polymorphisme
Humain, CEPH) (CEU, n=90). ACE genomic sequences in these
populations were characterized with a set of 75 SNPs.
First, from the set of 75 SNPs, 12 SNPs randomly distributed
throughout the ACE gene and homozygous in subject N1 were
chosen. Second, from the sets of individuals from these four
populations (YRI, JPT, CHB and CEU), patients who were
heterozygous for any of the 13 SNPs were excluded from further
analysis. Finally, we excluded haplotypes with information missing
for more than one chosen SNP. This selection procedure, which
we consider to be random in regard to SNPs and individuals,
yielded with data containing total of 100 individuals: n=25 of
CHB, n=19 of JPT, n=24 of YRI, and n=32 of CEU
population. This dataset was used for classification with PHYLIP;
the most parsimonious tree is presented in Fig. 7 (A). We identified
9 clades, although number of samples within each clade varied.
The haplotype of the N1’s mutant ACE allele was found to be
most similar to clade L1-1, which incorporates two Nigerians and
one Chinese (YRI-19211, YRI-18517 and CHB-18577). Due to
heterozygosity of some SNPs in the analyzed population, the
haplotype of N1’s mutant allele was found to be different from
clade L1-1. However, N1 can be a perfect match with any of L1-1
members (Fig. 7B) and, therefore, N1 and clade L1-1 can be
aggregated with high probability in a single clade.
Assignment of the N1 Haplotype to Earlier Identified
Clades
We performed further classification of the N1 haplotype in
relation to earlier identified clades associated with high and low
plasmaACElevelusingcladisticanalysis.Thefollowingpopulations
were analyzed: Caucasian British [48–49]; Nigerians, Jamaicans
and African-American [50]; and French [51]. Since different set of
SNPswere usedineach study,weperformed threeseparateanalyses
for N1 for every set of previously identified clades (Fig. 8). We found
one perfect match in all three clade systems: N1 was assigned in the
same clade with I-1, I-2, and I-7 clades of Yorubans from Nigeria
(Fig. 8B). Patient N1 haplotype was most similar to clades SA-
43904, SC-11136, and SC-11104 in the French population and to
A7, C3 and C4 clades in the British population (Fig. 8B).
Clinical Characterization of Subject N1 and Her Relatives
Subject N1 reported symptoms suggestive of asthma (cough, chest
tightness, and wheezing aggravated by cold air, dust exposure, and
upper respiratory infection), and her spirometry demonstrated mild
airflow obstruction that improved slightly acutely following inhaled
bronchodilator. Several additional first and second degree relatives
reported doctor-diagnosed asthma; when measured, spirometry
disclosed mild airflow obstruction in those with reported asthma,
and no airflow obstruction in those who denied having asthma. N1’s
father (N2) had moderate airflow obstruction on spirometry but had
smoked cigarettes. There was also a history of hypertension in N1’s
family, though subject N1 did not have hypertension herself. There
was no consistent relationship between the presence of high serum
ACE and clinical phenotype in N1’s family.
Discussion
Recently, a molecular mechanism underlying the marked (5-
fold) familial increase of plasma ACE was discovered: P1199L
Table 1. Activity and rate of ACE release from CHO cells
transfected with various ACEs.
ACE ACE activity (mU/ml)
Rate of ACE
release
Soluble ACE Membrane-bound % per 24 h
Wild-type* 3.460.2 82.069.1 11.360.8
Wild-type# 0.0660.2 2.360.1 7.860.4
Pro1199Leu# 6.460.4 29.762.1 48.965.1
Trp1197Stop# 12.060.4 7.762.1 83.562.0
Ser1211Stop#+ 4.460.3 3.860.3 80.160.6
Gln1230StopX*& 628639 195610 89.862.1
CHO cells transfected (stable or transient) with cDNA of human recombinant
wild-type ACE or indicated mutants were cultivated in 100 mm Petri dish in F12
medium with 10% FBS. Once cells become confluent, dishes were washed with
PBS and a fresh Ultra CHO medium (10 ml) were added. After 24 hours of
cultivation culture medium was collected, cells were washed with PBS and lysed
with 3 ml HEPES buffer (20 mM, pH 7.5, NaCl 150 mM) with 8 mM CHAPS.
ACE activity was determined in culture medium (soluble ACE) and in a lysate
(membrane-bound form) with Hip-His-Leu as a substrate and the rate of ACE
shedding was calculated (ACE activity in culture medium X 100/ACE activity in
culture medium + ACE activity in lysate).
*- Stable transfection:, # Transient transfection.
+ Plasmid with cDNA coding for this mutant was kindly provided by Dr. E.
Sturrock (University of Cape Town, South Africa).
& Plasmid with cDNA coding for this mutant was kindly provided by Dr. F.
Alhenc-Gelas (then INSERM U 367, Paris, France).
doi:10.1371/journal.pone.0008282.t001
New ACE Mutation (Trp1197Stop)
PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8282Figure 5. Conformational fingerprinting of mutated ACE with a set of mAbs to ACE. Data from the analysis of the precipitation of ACE
activity from wild type recombinant human ACE, and recombinant mutant ACEs by 16 mAbs to human ACE were expressed as a ratio of ACE
precipitation from Pro1199Leu mutant (A) or Trp1197Stop (B) to that for wild type ACE or ratio of ACE precipitation from Trp1197Stop to that from
Pro1199Leu mutation (C). Data presented as a mean of three independent determinations (which were not differ more than 10%) for each ratio.
*-p ,0.05 in comparison with values for wild type ACE (A and B) or with Pro1199Leu mutant (C).
doi:10.1371/journal.pone.0008282.g005
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secretase and for the enhancement of the cleavage-secretion
process [28–29]. We developed a convenient assay for the
detection of this particular mutation based on analysis of the
plasma ACE binding to mAb 1B3 (directed to the C-terminal part
of soluble ACE) and binding to mAb 9B9 (on the N-terminal
domain of ACE). The observed 1B3/9B9 binding ratio was 3-fold
lower for affected individuals, thus allowing identification of this
Figure 6. Western blot analysis of normal and mutant ACEs. A. ACE purified from plasma of patient N1, pooled plasma from 5 patients with
hyper-ACE-emia (carriers of Pro1199Leu mutation) and pooled plasma from 5 healthy individuals with normal blood ACE level were equilibrated to
50 mU/ml of ACE activity (HHL as a substrate), boiled and 40 and 20 ml of each sample run in 4–15% radient gel in reducing conditions. Proteins
transferred on PVDF-Plus membrane were revealed with 2 mg/ml of indicated mAb. Molecular weight is shown on the left. B. Revelation of blood ACE
presented in panel A was quantified by densitometry of the bands. Data presented as a ratio of density with mAb 5C8 to that with mAb 1D8.
Revelation of ACE from the blood of carriers of Pro1199Leu or Thr1197Stop (who contains a mixture of normal and mutated ACEs in their blood) by
mAb 5C8 dramatically diminished.
doi:10.1371/journal.pone.0008282.g006
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with high sensitivity and specificity and without labor-time and
cost-consuming sequencing or restriction analysis of the PCR
products [39].
Here, we identified a family in whom a novel mutation – in
which the codon TGG encoding Trp1197 is substituted in one
allele by TGA (stop codon) – results in 13-fold elevation of ACE
level in the blood. As a result of this mutation, half the ACE
expressed in heterozygous individuals had a length of 1196 amino
acids and lacked the transmembrane anchor, which starts from
Val1228 [52]. Previous studies show that different ACE mutants
that also lack the transmembrane anchor were directly secreted
into the circulation [16,53]. A similar mechanism accounts for
subject N1’s high serum ACE level.
The novel mutation carried by N1 can be detected using the
above mentioned antibody-based assay (Figs. 1–2). However,
although this approach identifies carriers of this new mutation
(W1197X), it does not allow one to distinguish this from a
previously described (P1199L) mutation. Therefore, we exploited
restriction site polymorphisms in the DNA sequence encoding
these two mutant isoforms (Fig. 3), implemented using PCR-
amplified segments of DNA spanning these mutations.
The assays we developed – an antibody-based assay (1B3/9B9
ratio) and a restriction analysis of the PCR product – distinguish
easily between elevation of blood ACE due to granulomatous
diseases (sarcoidosis in particular) or Gaucher disease and hyper-
ACE-emia due to lack of transmembrane domain, thus preventing
false diagnosis and unnecessary treatment. Despite the fact that
patients with the Pro1199Leu mutation exhibit no clinical
abnormalities [28], the search for these mutations is of
considerable clinical importance. Genetically determined elevation
of ACE level may lead to false diagnosis of sarcoidosis and
consequently to unnecessary long-term immunosuppresive treat-
ment [30].
This mutation raises an important question – how much ACE
(tissue and/or blood) is appropriate to maintain healthy condi-
tions? Individuals without any functional ACE may die in utero or
within 24 h of birth as a result of profound developmental
abnormality of proximal kidney tubules – renal tubular dysgenesis
[54–55]. In one family, a stop codon was introduced after Arg236
and in another family the correct sequence of ACE was through
Pro402 - mature somatic ACE numbering [10]. Therefore, in both
families affected homozygous individuals have no functional ACE.
The same type of renal lesions was seen in fetuses that were
exposed to ACE inhibitors [56]). Thus, it seems that for normal
renal development it is necessary to have at least some minimum
level of ACE, and as a consequence, a minimal level of
Angiotensin II (Ang II) during development. Also, it is necessary
to mention that mainly tissue ACE determines the conversion of
Ang I to Ang II. When we found several Dutch families with the
Pro1199Leu ACE mutation that leads to a 5-fold increase in blood
ACE (due to increase in ACE shedding), we determined Ang I and
And II levels in the affected subjects and in their unaffected
relatives. Ang I level in patients with 5-fold elevated ACE tended
to be only slightly (78%) lower than in controls, and this trend was
not statistically significant. Ang II in the ‘‘high-ACE’’ group was
just double that of the control group (5.0+5.0 versus
2.2+1.4 pmol/L in control group, p=0.034) [28]. Furthermore,
we would not expect to see a dramatic (much more than double)
increase in the blood level of Ang II of affected family members
because the levels of ACE in the tissues are more than an order of
magnitude higher than those in the blood. Therefore, an overall
conversion of Ang I to Ang II (per gram of any tissue) should not
be dramatically increased in the affected members of this family.
We believe that despite the fact that tissue ACE in N1 patient
should be just half of that of non-affected individuals, the huge
excess of blood ACE in this individual perhaps compensates for a
diminished level of tissue ACE. This possibility is supported by the
finding of Bernstein’s group, who demonstrated that the blood
pressure of mice lacking tissue ACE, but having 80% of blood
ACE, is indistinguishable from that of wild type mice [57].
Therefore, homeostasis can be maintained without the localized
production of Ang II [58].
The demonstration of renal tubular dysgenesis in humans
having no normal allele of ACE raises a serious question about the
non-identity of mouse models and human pathologies. In mice a
Table 2. Haplotype reconstruction of the paternal copy of ACE from patient N1.
Nomenclatures of the polymorphic markers of ACE gene*
HapMap Previous number [73] Rieder’s position [74] Localization Haplotype
rs4291 A-240 (-239)T 2400 Promoter A
rs4292 T-93C 2547 Promoter T
rs4309 T1237C 8125 Exon 8 C/T
rs4318 A7941G 10578 Exon 13 A
rs4331 G2215A 12257 Exon 15 A
rs4335 A10539G NA Intron 16 A
rs4340 Alu I/D 14095 Intron 16 D
rs4343 G2350A 14521 Exon 17 A
rs4353 A15990G 18912 Intron 20 A
rs4359 C17911T 20833 Intron 23 T
rs4362 NA 22251 Exon 24 T
rs4363 A20060G 22982 Intron 25 G
*Haplotype reconstruction of the paternal copy of the gene was based on sequencing of ACE from patient N1 and their parents. Novel mutation Trp1197Stop is located
in exon 25 between SNPs rs4362 and rs4363. Selected 12 SNP are presented in the Table.
NA- not analyzed.
doi:10.1371/journal.pone.0008282.t002
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tree for ACE haplotypes of individuals from four different ethnic origins and patient N1 is shown. Cladistic analysis was based on 13 informative
polymorphisms and revealed 6 levels of divergence. Detailed description of samples is shown only for first two levels; for higher divergence only
number of samples is indicated in parentheses. The size of boxes correlates with number of samples within the clade. Human populations were CEU,
Caucasians; JPT, Japan; YRI, Africans; CHB, Chinese; and N1, patient with Trp1197Stop mutation. N1 patient is similar to Nigerians YRI-19211 and YRI-
18517, and one Chinese CHB-18577. B. ACE genotypes and haplotypes for patient N1 and individuals from levels 1, 2 and 3 are shown. Positions
highlighted in green were conservative in all shown individuals. Polymorphic nucleotides in N1 are highlighted in red, and show in alternative colors
(yellow vs. blue) in other clades/individuals. Some positions were C/T or A/G heterozygous; or genotyping data were missing (N/N). SNPs (‘‘rs’’ with
number), position of the I/D polymorphism, and the position of W1197X mutation in N1 are shown on the top of the table. Linkage disequilibrium
plot for Nigerian population is presented on the bottom (source: International HapMap project at http://www.hapmap.org).
doi:10.1371/journal.pone.0008282.g007
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dysgenesis; ACE knock-out mice are hypotensive and are unable
to effectively concentrate urine. This functional renal defect
accompanies structural kidney malformation typified by underde-
velopment of renal medulla and papilla (59). However fetuses of
ACE knockout mice did not die in utero and at birth the kidneys
from ACE knockout mice are structurally indistinguishable from
those of wild-type littermate controls [3]. Differences in the renal
phenotype between humans and mice are not fully understood,
though it has been suggested that differences in the timing of
nephrogenesis explain the discrepancy [55,60]. We think that
dramatic differences in ACE activity in organs and blood of mice
and human also might play a role: ACE activity in mouse blood
and tissues is 10-fold more that in human. Therefore in human
with absence of ACE [54,60], the level of Ang II might fall below
some level critical for normal kidney development.
Our data indicate that W1197X mutation is not a spontaneous
event that occurred de novo in subject N1, but rather it was inherited
from earlier generations. Therefore, we hypothesized that cladistic
analysis will help us to identify distant relatives of subject N1, which
would allow the identification of additional individuals with N1’s
phenotype. For this purpose, we analyzed human populations of four
different ethnic/geographic origins with representative set of 12 SNPs.
Haplotypes clustering did not resolve ethnic groups in four
independent clades, although significant correlation of ACE haplotypes
with geographical origin was demonstrated. Most remarkably, we
found a perfect match for patient N1 ACE haplotype with two
individuals from Nigeria. Taking into account that N1 is an African
American, we hypothesize that mutation W1197X occurred at least
several hundreds years ago in Africa in a grand ancestor of N1 and
Nigerians YRI-18517 and YRI-19111. If this is true, there is a good
chance to find other carriers of the mutation in Nigeria. However,
similarity between haplotypes of N1 and Chinese CHB-18577 might
be attributable either to common origin of these haplotypes further
back in human history or to spontaneous re-creation of haplotype L1-1
in Africa and China due to evolution convergence.
In all three populations, cladistic analysis shows that N1 fits into ‘‘D’’
type of Alu-I/D polymorphism (Fig. 8B), the type, as it was shown
earlier, correlates with higher plasma ACE level [49]. On a more
detailed scale, when a greater number of SNPs was employed, N1’s
haplotype also clustered with clades representing higher plasma ACE
level. For instance, in the French population, clade ‘‘C’’ (members SA-
Figure 8. Clustering of the patient N1 haplotype into ACE clades. A. Clustering of the patient N1 haplotype along clades identified in French
[51], British [48] and African-originated [50] populations. B B. Detailed haplotypes of identified clades and N1 are presented. N1 carrier of the W1197X
mutation perfectly matched with Africa-originated clade I (sub-clades 1, 2, and 7) and was consistently associated with clades represented high ACE
plasma level (see text).
doi:10.1371/journal.pone.0008282.g008
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increase of z-score for ACE activity in plasma as compared to clade A
[51] (Fig. 8B). In the British population, N1 haplotype was closest to
Alu-D-type clade ‘‘C’’ (C3, C4) from study of Keavney et al [48].
Individuals from clade ‘‘C’’ have plasma ACE level 68% higher than
patients from clade ‘‘A’’ [48].
In the African population, N1’s haplotype was identical to three
clades (I-1, I-2, I-7) found originally by Bourzekri with coauthors
[50]. This supports the possibility that the Trp1197Stop mutation
occurs with significant frequency in Nigeria. It was demonstrated
that polymorphism rs4343 (ACE8 according to author’s notation)
was extremely highly associated (p,10
-17) with elevated serum
concentration of ACE. The best model to fit ACE polymorphisms
(n=6) and plasma level in all studied populations (Nigeria,
Jamaica, and US) showed the highest association in Nigerians.
ACE8 SNP alone was attributed to as much as 21% of the total
ACE serum level variance in Nigerian individuals [50].
Taking together data on association of higher ACE sera level
with Alu-D-type polymorphism and with downstream rs4343
SNP, we address the question on possible linkage disequilibrium in
the area of ACE flanked with these two polymorphisms. Indeed,
linkage disequilibrium (LD) analysis shows that recombinations in
this area are rare (LD plot on the bottom of Fig. 7B). This implies
that Alu-D-type might associate with higher ACE serum activity
because of the tight linkage with functional polymorphisms, which
belong to stalk domain of ACE. The novel Trp1197Stop mutation
we found in subject N1 is one of the best examples of functional
SNPs of this kind. Additionally, in the study of Bourzekri et al.
[50], the highest association with high serum level of ACE was also
demonstrated for the SNP located close to stalk region.
Thus, we can consider at least two different mechanisms for
regulation of ACE activity in blood. One mechanism is reliant
upon control of gene expression and genetically linked both to loci
in promoter region of the gene and other loci in genome. A second
way to control ACE level in blood is reliant on spontaneous
alterations within stalk region of the gene/protein. The previously
identified Pro1199Leu mutation [28] and the most recently
discovered Trp1197Stop mutation (this study) are two examples
of this mode of regulation of ACE activity.
Might very high level of blood ACE in subject N1 and in affected
members of her family play a role in the mild airflow obstruction
seen in affected individuals? There are plausible potential
mechanisms by which elevated blood ACE might promote features
of asthma pathology. Excessive accumulation of airway smooth
muscle, due to hyperplasia and/or hypertrophy [61], is a common
occurrence in asthmatic airways. Ang II, generated through
hydrolysis of Ang I by ACE, stimulates vascular smooth muscle
cell growth both in vitro [62] and in vivo [63]. Ang II promotes airway
myocyte hypertrophy in vitro [64]. Perhaps high blood levels of Ang
II (due to constitutively high level of blood ACE) might have a
similar effect on airway myocytes in vivo. Ang II can also contract
humanbronchialrings[65].Interestingly,increasedplasmalevels of
Ang II have been reported in acute severe asthma [66–67], and iv
infusion of Ang II in mild asthmatics can cause bronchoconstriction
[66]. Furthermore, Ang II potentiates methacholine-induced
bronchoconstriction [65]. Recently, it was also shown that locally
generated Ang II causes bronchoconstriction in guinea pigs [68].
Another theoretical mechanism by which subject N1’s mutation
might have contributed to her airflow obstruction could relate to
accelerated bradykinin (BK) metabolism. BK is another substrate
for ACE, perhaps the ‘‘best’’ with the highest Km [1–2], and is a
potent vasodilator that induces cough and bronchoconstriction in
subjects with asthma [69–70]. Perhaps decreased ACE tissue levels
increase local tissue concentration of BK and so promote asthma
symptoms.
Additional implication of a potential role of ACE in asthma
comes from analysis of an ACE insertion/deletion (I/D)
polymorphism in different asthmatic populations. The homozy-
gous deletion (DD) genotype is associated with minor elevation of
serum ACE activity: individuals with this genotype have 60–70%
more ACE in the blood than carriers of the II genotype and
approximately 30–40% more than the whole population mean
[33,71]. In some but not all studies (reviewed in [72]), the DD
genotype is associated with asthma. Although these findings might
have suggested that the extremely high blood ACE levels in N1
and her family contribute to their asthma, in the limited
population we studied we found no significant association between
the presence of the W1197X mutation and asthma. Thus, if the
mutation is at all contributory, it does not appear to be a dominant
predisposing factor in N1’s family.
In summary, we have identified a novel W1197X mutation that
results in dramatic elevation of serum ACE, and which can occur
in individuals of African American descent who have mild airflow
obstruction. Because the constellation of airflow obstruction and
elevated serum ACE in African American individuals is one that
should raise the possibility of sarcoidosis to pulmonologists, it is
important to recognize that mutations of the ACE gene that are
not associated with disease – including the novel W1197X
mutation reported here – can also lead to substantial blood
ACE elevation. Thus, whenever very high serum ACE is found in
the evaluation of potential sarcoidosis cases, we recommend that
evaluation for the W1197X and P1199L mutations should be
considered.
Acknowledgments
The authors thank subject N1 and her family for their cooperation. We are
grateful to Dr. F. Alhenc-Gelas (then INSERM U367, Paris, France) and
Dr. E. Sturrock (University of Cape Town, South Africa) for providing us
plasmids coding a mutant forms of human somatic ACE: Q1230X and
S1211X, respectively, and to Dr. R. Stein (Penobscot Bay Medical Center,
Rockport, ME) providing us DNA from patient having P1199L substitution
in ACE.
The authors thank Dr. Yu. Berestetskaya (then University of Illinois at
Chicago) for initial isolation of genomic DNA of subject N1. The authors
would like to acknowledge the helpful discussion with Dr. Jaap Deinum
(University of Nijmegen, The Netherlands). The authors also thank Dr.
Martin Farrall (Wellcome Trust Center for Human Genetics, University of
Oxford, UK) for critical reading of the manuscript. We acknowledge
technical assistance of J. Martin (University of Illinois at Chicago). Our
special thank is to DNA sequencing facility of University of Illinois at
Chicago and, particularly, Annette Bruno.
Footnotes: Part of the work was presented at ATS 2007 International
Conference, San Francisco, May 18–23, 2007 and was published as an
abstract in American Journal of Respiratory and Critical Care Medicine, v. 175,
2007 (Nesterovitch et al., A462).
Author Contributions
Conceived and designed the experiments: ABN VAA JS SMD. Performed
the experiments: ABN KDH EIV SMD. Analyzed the data: ABN KDH
VAA DES JS SMD. Wrote the paper: VAA JS SMD.
References
1. Ehlers MR, Riordan JF (1989) Angiotensin-converting enzyme: new concepts
concerning its biological role. Biochemistry 8: 5311–5318.
2. Corvol P, Eyries M, Soubrier F (2004) Peptidyl-dipeptidase A/Angiotensin
I-converting enzyme. In: Barret A, Rawlings N, Woessner J, eds. Handbook
New ACE Mutation (Trp1197Stop)
PLoS ONE | www.plosone.org 13 December 2009 | Volume 4 | Issue 12 | e8282of Proteolytic Enzymes. New York: Elsevier Academic Press. pp 332–
349.
3. Bernstein KE, Xiao HD, Frenzel K, Li P, Shen XZ, et al. (2005) Six truisms
concerning ACE and the renin-angiotensin system educed from the genetic
analysis of mice. Circ Res 96: 1135–1144.
4. Caldwell PR, Seegal BC, Hsu KC, Das H, Soffer RL (1976) Angiotensin-
converting enztme: vascular endothelial localization. Science 191: 1050–1051.
5. Defendini R, Zimmerman EA, Weare JA, Alhenc-Gelas F, Erdos EG (1983)
Angiotensin-converting enzyme in epithelial and neuroepithelial cells. Neuro-
endocrinology 37: 32–40.
6. Hooper NM, Turner AJ (1987) Isolation of two differentially glycosylated forms
of peptidyl-dipeptidase A (angiotensin-converting enzyme) from pig brain: a re-
evaluation of their role in neuropeptide metabolism. Biochem J 241: 625–633.
7. Franke FE, Metzger R, Bohle R-M, Kerkman L, Alhenc-Gelas F, et al. (1997)
Angiotensin I-Converting Enzyme (CD 143) on endothelial cells in normal and
in pathological conditions. In: Kishimoto T, et al., eds. Leucocyte Typing VI: White
Cell Differentiation Antigens. New York: Garland Publishing Inc. pp 749–751.
8. Silverstein E, Friedland J, Setton C (1978) Angiotensin-converting enzyme in
macrophages and Freund’s adjuvant granuloma. Isr J Med Sci 14: 314–318.
9. Danilov SM, Sadovnikova E, Scharenbourg N, Balysnikova IV, Svinareva DA,
et al. (2003) Angiotensin-converting enzyme (CD143) is abundantly expressed by
dendritic cells and discriminates human monocytes-derived dendritic cells from
acute myeloid leukemia-derived dendritic cells. Exp Hem 31: 1301–1309.
10. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, et al. (1988) Two
putative active centers in human angiotensin I-converting enzyme revealed by
molecular cloning. Proc Natl Acad Sci USA 85: 9386–9390.
11. Ehlers MR, Fox EA, Strydom DJ, Riordan JF (1989) Molecular cloning of
human testicular angiotensin-converting enzyme: the testis isozyme is identical
to the C-terminal half of endothelial ACE. Proc Natl Acad Sci USA 86:
7741–7745.
12. Lattion AL, Soubrier F, Allegrini J, Hubert C, Corvol P, et al. (1989) The
testicular transcript of the angiotensin I-converting enzyme encodes for the
ancestral, non-duplicated form of the enzyme. FEBS Lett 252: 99–104.
13. Danilov SM, Franke FE, Erdos EG (1997) Angiotensin-Converting Enzyme
(CD143). In: Leucocyte Typing VI: White Cell differentiation Antigens. T. Kishimoto T.
et al., editors. New York: Garland Publishing Inc. pp 746–749.
14. Ching SF, Hayes LW, Slakey LL (1983) Angiotensin-converting enzyme in
cultured endothelial cells. Synthesis, degradation and transfer to culture
medium. Arteriosclerosis 3: 581–588.
15. Hooper NM, Keen J, Pappin DJC, Turner AJ (1987) Pig kidney angiotensin
converting enzyme. Purification and characterization of amphipatic and
hydrophilic forms of the enzyme establishes C-terminal anchorage to the
plasma membrane, Biochem J 247: 85–93.
16. Wei L, Alhenc Gelas F, Soubrier F, Michaud A, Corvol P, et al. (1991)
Expression and characterization of recombinant human angiotensin I-convert-
ing enzyme. Evidence for a C-terminal transmembrane anchor and for a
proteolytic processing of the secreted recombinant and plasma enzymes. J Biol
Chem 266: 5540–5546.
17. Woodman ZL, Oppong SY, Cook S, Hooper NM, Schwager SL, et al. (2000)
Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient
compared with testis ACE despite cleavage at identical stalk sites. Biochem J
347: 711–718.
18. Parkin ET, Turner AJ, Hooper NM (2004) Secretase-mediated cell surface
shedding of the angiotensin-converting enzyme. Protein Pept Lett 11: 423–432.
19. Pauls K, Metzger R, Steger K, Klonisch T, Danilov S, et al. (2003) Isoforms of
angiotensin I-converting enzyme in the development and differentiation of
human testis and epididymis. Andrologia 35: 32–43.
20. Alhenc-Gelas F, Richard J, Courbon D, Warnet JM, Corvol P (1991)
Distribution of plasma angiotensin I-converting enzyme levels in healthy men:
Relationship to environmental and hormonal parameters. J Lab Clin Med 117:
33–39.
21. Lieberman J (1975) Elevation of serum angiotensin-converting enzyme level in
sarcoidosis. Am J Med 59: 365–372.
22. Lieberman J, Beutler E (1976) Elevation of angiotensin-converting enzyme in
Gaucher’s disease. N Engl J Med 294: 1442–1444.
23. Silverstein E, Friedland J, Lyons HA, Gourin A (1976) Elevation of angiotensin-
converting enzyme in granulomatous lymph nodes and serum in sarcoidosis:
clinical and possible pathological significance. Ann NY Acad Sci 278: 498–513.
24. Studdy P, Bird R, James DG, Sherlock S (1978) Serum angiotensin-converting
enzyme in sarcoidosis and other granulomatous disorders. Lancet 2: 1331–1334.
25. Ainslie GM, Benatar SR (1985) Serum angiotensin-converting enzyme in
sarcoidosis: sensitivity and specificity in diagnosis: correlation with disease
activity, duration, extra-thoracic involvement, radiographic type and therapy.
Q J Med 55: 253–270.
26. Lieberman J (1989) Enzymes in sarcoidosis: Angiotensin-converting enzyme
(ACE). Clinics in Laboratory Medicine 9: 745–755.
27. Beneteau-Burnat B, Baudin B (1991) Angiotensin-converting enzyme: clinical
applications and laboratory investigation n serum and other biological fluids.
Crit Rev Clin Lab Sci 28: 337–356.
28. Kramers C, Danilov SM, Deinum J, Balyasnikova IV, Scharenborg N, et al.
(2001) Point mutation in the stalk of angiotensin-converting enzyme causes a
dramatic increase in serum angiotensin-converting enzyme but no cardiovas-
cular disease. Circulation 104: 1236–1240.
29. Eyries M, Michaud A, Deinum J, Aagrapart M, Chomillier J, et al. (2001)
Increased shedding of angiotensin-converting enzyme by a mutation identified in
the stalk region. J Biol Chem 276: 5525–5532.
30. Linnebank M, Kesper K, Jeub M, Urbach H, Wullner U, et al. (2003)
Hereditary elevation of angiotensin-converting enzyme suggesting neurosarcoi-
dosis. Neurology 61: 1819–1820.
31. Semmler A, Stein RW, Caplan L, Danilov SM, Klockgether T, et al. (2006)
Hereditary hyper-ACE-emia due to the Pro1199Leu mutation of somatic ACE
as a potential pitfall in diagnosis: a first family out of Europe. Clin Chem Lab
Med 44: 1088–1089.
32. Kramers C, Deinum J (2003) Increased serum activity of angiotensin-converting
enzyme (ACE): indication of sarcoidosis? A Bayesian approach. Ned Tijdschr
Geneeskd 147: 473–476.
33. Danilov SM, Savoie F, Lenoir B, Jeunemaitre X, Azizi M, et al. (1996)
Development of enzyme-linked immunoassays for human angiotensin I-
converting enzyme suitable for large-scale studies. J Hypertens 14: 719–727.
34. Piquilloud Y, Reinharz A, Roth M (1970) Studies on the angiotensin-converting
enzyme with different substrates. Biochim Biophys Acta 206: 136–142.
35. Friedland J, Silverstein E (1976) A sensitive fluorometric assay for serum
angiotensin-converting enzyme. Am J Pathol 66: 416–424.
36. Danilov S, Jaspard E, Churakova T, Towbin H, Savoie F, et al. (1994)
Structure-function analysis of angiotensin I-converting enzyme using monoclo-
nal antibodies. J Biol Chem 269: 26806–26814.
37. Felsenstein J (1997) An alternating least squares approach to inferring
phylogenies from pairwise distances. Syst Biol 46: 101–111.
38. Balyasnikova IV, Gavriljuk VD, McDonald TD, Berkowitz R, Miletich DJ, et al.
(1999) Antibody-mediated lung endothelium targeting: In vitro model using a
cell line expressing angiotensin-converting enzyme. Tumor Targeting 4: 70–83.
39. Danilov SM, Deinum J, Balyasnikova IV, Sun ZL, Kramers C, et al. (2005)
Detection of mutated angiotensin I-converting enzyme by serum/plasma
analysis using a pair of monoclonal antibodies. Clin Chem 51: 1040–1043.
40. Balyasnikova IV Skirgello OE, Binevski PV, Nesterovitch AB, Albrecht RFII,
et al. (2007) Monoclonal antibodies 1G12 and 6A12 to the N-domain of human
angiotensin-converting enzyme: fine epitope mapping and antibody-based
method for revelation and quantification of ACE inhibitors in the human
blood. J Proteome Res 6: 1580–1594.
41. Beldent V, Michaud A, Bonneloy C, Chauvet MT, Corvol P (1995) Cell surface
localization of proteolysis of human endothelial angiotensin I-converting
enzyme. Effect of the amino-terminal domain on the solubilization process.
J Biol Chem 270: 28963–228969.
42. Alfalah M, Parkin ET, Jacob R, Sturrock ED, Mentele R, et al. (2001) A point
mutation in the juxtamembrane stalk region of human angiotensin I-converting
enzyme invokes the action of a distinct secretase. J Biol Chem 276:
21105–21109.
43. Balyasnikova IV, Woodman ZL, Albrecht RFII, Natesh R, Acharya KR, et al.
(2005) Localization of an N domain region of angiotensin-converting enzyme
involved in the regulation of ectodomain shedding using monoclonal antibodies.
J Proteome Res 4: 258–267.
44. Skirgello OE, Balyasnikova IV, Binevski PV, Sun Z-L, Baskin II, et al. (2006)
Inhibitory antibodies to human angiotensin-converting enzyme: fine epitope
mapping and mechanism of action. Biochemistry 45: 4831–4847.
45. Danilov SM, Watermeyer JM, Balyasnikova IB, Gordon K, Kugaevskaya EV,
et al. (2007) Fine epitope mapping of mAb 5F1 reveals anticatalytic activity
toward the N domain of human angiotensin-converting enzyme. Biochemistry
46: 9019–9031.
46. Balyasnikova IB, Metzger R, Franke FE, Towbin H, Gordon K, et al. (2008)
Epitope mapping of mAbs to denatured human testicular ACE. Tissue Antigens
72: 354–368.
47. Balyasnikova IV, Sun Z-L, Berestetskaya YV, Albrecht RAII, Sturrock ED, et al.
(2005) Monoclonal antibodies 1B3 and 5C8 as probes for monitoring the nativity
of C-terminal end of soluble angiotensin-converting enzyme (ACE). Hybridoma
24: 14–26.
48. Keavney B, McKenzie CA, Connell JM, Julier C, Ratcliffe PJ, et al. (1998)
Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum
Mol Genet 7: 1745–1751.
49. Farrall M, Keavney B, McKenzie CA, Delepine M, Matsuda F, et al. (1999)
Fine-mapping of an ancestral recombination breakpoint in DCP1. Nat Genet
23: 270–271.
50. Bouzekri N, Zhu X, Jiang Y, McKenzie CA, Luke A, et al. (2004) Angiotensin I-
converting enzyme polymorphisms, ACE level and blood pressure among
Nigerians, Jamaicans and African-Americans. Eur J Hum Genet 12: 460–468.
51. Soubrier F, Martin S, Alonso A, Visvikis S, Tiret L (2002) High-resolution
genetic mapping of the ACE-linked QTL influencing circulating ACE activity.
Eur J Hum Genet 10: 553–561.
52. Chubb AJ, Schwager SL, Woodman ZL, Ehlers MR, Sturrock ED (2002)
Defining the boundaries of the testis angiotensin-converting enzyme ectodo-
main. Biochem Biophys Res Commun 297: 1225–1230.
53. Ehlers MRW, Chen YNP, Riordan JF (1991) Spontaneous solubilization of
membrane-cound testis angiotensin-converting enzyme expressed in Chinese
hamster ovary cells. Proc Natl Acad Sci USA 88: 1009–1013.
54. Gribouval O, Gonzales M, Neuhaus T, Aziza J, Bieth E, et al. (2005) Mutations
in genes in the renin-angiotensin system are associated with autosomal recessive
renal tubular dysgenesis. Nature Genetics 37: 964–968.
New ACE Mutation (Trp1197Stop)
PLoS ONE | www.plosone.org 14 December 2009 | Volume 4 | Issue 12 | e828255. Corvol P, Michaud A, Gribouval O, Gasc J-M, Gubler M-C (2008) Can we live
without a functional renin-angiotensin system? Clin Exp Pharmacol Physiol 35:
431–433.
56. Barr M, Cohen MM (1991) ACE inhibitor fetopathy and hypocalvaria. The
kidney skull connection. Teratology 44: 485–495.
57. Cole J, Quach DL, Sundaram K, Corvol P, Capecchi M, et al. (2002) Mice
lacking endothelial angiotensin-converting enzyme have a normal blood
pressure. Circ Res 90: 87–92.
58. Shen XZ, Xiao HD, Li P, Lin C, Fuchs S, et al. (2008) Tissue specific expression
of angiotensin converting enzyme: A new way to study an old friend. Int
Immunopharmacol 8: 171–176.
59. Fuchs S, Xiao H, Cole JM, Adams JW, Frenzel K, et al. (2004) Role of the
terminal catalytic domain of angiotensin-converting enzyme investigated by
targeted inactivation in mice. J Biol Chem 279: 15946–15963.
60. Lacoste M, Cai Y, Guicharnaud L, Mounier F, Dumez Y, et al. (2006) Renal
tubular dysgenesis, a not uncommon autosomal recessive disorder leading to
oligohydramnios: Role of the Renin-Angiotensin system. J Am Soc Nephrol 17:
2253–2263.
61. Ebina M, Takahashi T, Chiba T, Motomiya M (1993) Cellular hypertrophy and
hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D
morphometric study. Am Rev Respir Dis 148: 720–726.
62. Naftilan AJ (1992) The role of angiotensin II in vascular smooth muscle cell
growth. J Cardiovasc Pharmacol 20 (Suppl 1): S37–S40.
63. Griffin SA, Brown WCB, MacPherson F, McGrath JC, Wilson VG (1991)
Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism.
Hypertension 17: 626–635.
64. McKay S, de Jongste JC, Saxena PR, Sharma HS (1998) Angiotensin II induces
hypertrophy of human airway smooth muscle cells: expression of transcription
factors and transforming growth factor-beta1. Am J Respir Cell Mol Biol 18:
823–833.
65. Millar EA, Nally JE, Thomson NC (1995) Angiotensin II potentiates
methacholine-induced bronchoconstriction in human airway both in vitro and
in vivo. Eur Respir J 8: 1838–1841.
66. Millar EA Angus RA, Hulks G, Morton JJ, Connell JMC, et al. (1994) Activity of
the renin-angiotensin system in acute severe asthma and the effect of angiotensin
II on lung function. Thorax 49: 492–495.
67. Ramsay SG, Dagg KD, McKay IC (1997) Investigations on the renin-
angiotensin system in acute severe asthma. Eur Respir J 10: 2766–2771.
68. Veerappan A, Reid AC, Esthephan R, O’Connor N, Thadani-Mulero M, et al.
(2008) Mast cell renin and local rennin-angiotensin system in the airway: Role in
bronchoconstriction. Proc Natl Acad Sci USA 105: 1315–1320.
69. Barnes PJ (1997) Bradykinin, In: Barnes P, Grunstein M, Leff A, Woolcock A,
eds. Asthma. New York: Lippincott-Roven. pp 577–584.
70. Ricciardolo FLM, Timmers MC, Sont JK, Folkerts G, Sterk PJ (2003) Effect of
bradykinin on allergen induced increase in exhaled nitric oxide in asthma.
Thorax 58: 840–845.
71. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, et al. (1990) An
insertion/deletion polymorphism in the angiotensin I-converting enzyme gene
accounting for half the variance of serum enzyme levels. J Clin Invest 86:
1343–1346.
72. Lue KH, Ku MS, Li C, Sun HL, Lee HS, et al. (2006) ACE gene polymorphism
might disclose why some Taiwanese children with allergic rhinitis develop
asthma symptoms but others do not. Pediatr Allergy Immunol 17: 508–513.
73. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, et al. (1996)
Identification of new polymorphisms of the angiotensin I-converting enzyme
(ACE) gene, and study of their relationship to plasma ACE levels by two-QTL
segregation-linkage analysis. Am J Hum Genet 58: 1268–1278.
74. Rieder MJ, Taylor SL, Clark AG, Nickerson DA (1999) Sequence variation in
the human angiotensin converting enzyme. Nat Genet 22: 59–62.
New ACE Mutation (Trp1197Stop)
PLoS ONE | www.plosone.org 15 December 2009 | Volume 4 | Issue 12 | e8282